Merck's Keytruda gets NICE backing at discount; S.A.'s Aspen scouting for deals; Amgen opens new Irish facility;

@FiercePharma: Join @JohnCFierce for expert discussion on trial design and more at the @FierceBiotech Executive Summit on Oct. 12. More info | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Deal stalker Concordia snaps up Amdipharm in 'pivotal turning point' for M&A strategy. Article | Follow @CarlyHFierce

> Merck & Co.'s ($MRK) new cancer immunotherapy Keytruda won backing from the U.K.'s cost-effectiveness watchdogs after offering an unspecified discount. Report

> Aspen Pharmacare, the South African generics maker, is looking for deals after a 46% increase in international sales helped boost its first-half profits. Report

> Amgen ($AMGN) officially opened its new $300 million production facility in Ireland. Report

> The Germany-based drugmaker Stada re-upped on its contract with CEO Hartmut Retzlaff, retaining him to run the company for 5 more years. Report

> Canadian regulators cleared Recordati's rare disease drug Carbaglu for marketing, as a treatment for hyperammonemia. Report

> India's drug market is expected to hit $32.7 billion by 2020, up from $15.4 billion in 2014. Report

Medical Device News

@FierceMedDev: Cofactor Genomics chases consumer testing with RNA diagnostic. More from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: $1M+ raised on Indiegogo for company making maskless device for sleep apnea. Article | Follow @VarunSaxena2

@EmilyWFierce: Scientists NASA turbocharge 3-D imaging device for minimally invasive surgeries. Article | Follow @EmilyWFierce

> Study: Cancer-cell mopping implant could stop disease in its tracks. Story

> Tandem gains FDA approval for the second CGM-integrated, insulin pump. Article

Biotech News

@FierceBiotech: Star team at Wyss, MIT orchestrate wider use of CRISPR/Cas9 tech. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: And to mark 3 trial disasters in a row: Flexion routed as lead pain drug flops in first pivotal study. Article | Follow @JohnCFierce

@DamianFierce: ICYMI: NYT editorial takes a weird, non-systemic middle ground on PCSK9 pricing. Article | Follow @DamianFierce

> Roche backs AveXis in a $65M round for SMA gene therapy. Article

> Agenus mortgages some vaccine royalties for $115M in R&D cash. More

> On a crash course with Celgene? Biogen inks a $544M autoimmune drug deal. Story

> On the ropes, GlaxoSmithKline admits to another PhIII debacle. Report

Biotech Research News

> UC San Diego study IDs experimental drug for rare neurological disease. More

> Penn scientists identify viral products that defend against respiratory syncytial virus. Story

> Researchers zero in on tau, a prime culprit in Alzheimer's disease. Item

> Michigan team spotlights a new drug target for depression. Article

> Star team at Wyss, MIT orchestrate wider use of CRISPR/Cas9 tech. Report

Diagnostics News

> FDA clears Nanosphere's respiratory pathogens diagnostic test. News

> FDA pencils in two public meetings for NGS regulation. Item

> Moffitt Cancer Center, Signal Genetics to conduct 'precision medicine' study of myeloma patients. Report

> Beleaguered HDL mulls $32M sale to True Health amid bankruptcy. Story

> Cofactor Genomics chases consumer testing with RNA diagnostic. Article

Pharma Marketing News

> Big Pharma misses the cut for new list of top healthcare tweeters. More

> Sanofi agrees to pay $2.4M to Zaltrap sales reps in fight over discounted commissions. Report

> J&J's new multiple myeloma fighter gets FDA priority review. Item

> Bristol-Myers oncology team gears up for cycling fundraiser. Story

> Kardashian's FDA infraction shows policing pharma social media isn't easy. Article

And Finally... About half of U.S. adults have either diabetes or prediabetes, a study found, with one-third of diabetics as yet undiagnosed. Report

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.